Kymera Therapeutics vs Vir Biotechnology
KYMR and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KYMR and VIR compare
Kymera Therapeutics is the larger company, worth 6.6 times as much as Vir Biotechnology ($10.4B against $1.6B).
Vir Biotechnology grew revenue faster over the last twelve months (1496% versus 134% for Kymera Therapeutics).
Vir Biotechnology keeps more of each dollar of sales as profit, with a net margin of −83.0% compared with −342% at Kymera Therapeutics.
Vir Biotechnology scores higher on the StockData Score (11 against 9 for Kymera Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KYMR | VIR |
|---|---|---|
| Size and price | ||
| Market cap | $10.4B | $1.6B |
| Share price | $121.52 | $9.25 |
| Change, 1 year | 87.1% | 64.3% |
| Change, 5 years | 126% | −74.3% |
| Beta (5Y) | 0.59 | 0.80 |
| Employees | 238 | 367 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 101× | 5.2× (better) |
| P/B | 6.4× | 1.6× (better) |
| FCF yield | −2.8% (better) | −13.0% |
| Fair value | $37.15 | $13.31 |
| Margin of safety | −227% | 30.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 134% | 1496% (better) |
| Revenue growth, 5Y average | 2.9% (better) | −2.1% |
| Profitability | ||
| Gross margin | 0.00% | – |
| Operating margin | −396% | −92.4% (better) |
| Net margin | −342% | −83.0% (better) |
| FCF margin | −283% | −67.1% (better) |
| Return on equity | −27.3% | −26.1% (better) |
| Return on invested capital | −59.0% | −55.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.13 (better) | 6.04 |
| Altman Z-score | 39.62 (better) | 2.57 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 86.6% |
| Held by insiders | 38.3% | 17.1% |
| Insider net buying, 12 months | −$301M | −$4.0M (better) |
| Short interest, % of float | 16.0% | 12.0% |
Go deeper
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
- VIR stock overview
- VIR income statement
- VIR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.